Diadema Partners LP
MORRISTOWN, NJ
$265m in 77 US stocks at the end of 30 June 2026. The top 10 are 62.7% of the money. It changed about 47.7% of the portfolio this quarter.
Value
$265m
Stocks
77
Top 10 share
62.7%
Turnover
47.7%
What changed this quarter
New
Bought for the first time this quarter.
- Edgewise TherapeuticsEWTX4.2% of the fund
- 4D Molecular TherapeuticsFDMT2.9% of the fund
- Relay TherapeuticsRLAY1.6% of the fund
- Taysha Gene TherapiesTSHA1.3% of the fund
- Nurix TherapeuticsNRIX1.1% of the fund
- Oruka TherapeuticsORKA1.0% of the fund
- Vera TherapeuticsVERA0.9% of the fund
- Contineum TherapeuticsCTNM0.7% of the fund
- Viridian TherapeuticsVRDN0.7% of the fund
- ArdelyxARDX0.6% of the fund
- Cue BiopharmaCUE0.6% of the fund
- Prothena Corp PublicPRTA0.6% of the fund
- Spyre TherapeuticsSYRE0.5% of the fund
- Helus PharmaHELP0.5% of the fund
- Cartesian TherapeuticsRNAC0.3% of the fund
- Rigel PharmaceuticalsRIGL0.3% of the fund
- Summit TherapeuticsSMMT0.3% of the fund
- Definium TherapeuticsDFTX0.3% of the fund
- Cellectar BiosciencesCLRB0.1% of the fund
- AmgenAMGN<0.1% of the fund
- Heron TherapeuticsHRTX<0.1% of the fund
- Lakeland IndustriesLAKE<0.1% of the fund
- MeiraGTx HoldingsMGTX<0.1% of the fund
- JATT II AcquisitionJATT<0.1% of the fund
- Kailera TherapeuticsKLRA<0.1% of the fund
Added
Bought more of a stock they already held.
- United TherapeuticsUTHR10.9% of the fund+94%
- Revolution MedicinesRVMD9.9% of the fund+72%
- Abivax SAABVX8.2% of the fund+115%
- Cogent BiosciencesCOGT7.2% of the fund+53%
- Biomarin PharmaceuticalBMRN6.8% of the fund+111%
- Kodiak SciencesKOD3.2% of the fund+13%
- Immunocore HldgsIMCR3.1% of the fund+32%
- Novo Nordisk A SNVO1.8% of the fund+586%
- Corvus PharmaceuticalsCRVS1.7% of the fund+20%
- BioAge LabsBIOA1.4% of the fund+144%
- InventivaIVA1.0% of the fund+110%
- VaxcytePCVX1.0% of the fund+80%
- Relmada TherapeuticsRLMD0.9% of the fund+80%
- ProQR TherapeuticsPRQR0.7% of the fund+414%
- Spruce BiosciencesSPRB0.6% of the fund+200%
- Mineralys TherapeuticsMLYS0.6% of the fund+114%
- Unicycive TherapeuticsUNCY0.5% of the fund+186%
- Phathom PharmaceuticalsPHAT0.5% of the fund+138%
- PrecigenPGEN0.3% of the fund+145%
- PepGenPEPG0.3% of the fund+147%
- Enliven TherapeuticsELVN0.2% of the fund+3982%
Cut
Sold some of their stake.
- Viking TherapeuticsVKTX6.5% of the fund-16%
- Arcus BiosciencesRCUS2.6% of the fund-6%
- Johnson & JohnsonJNJ2.1% of the fund-59%
- Corbus Pharmaceuticals HoldingsCRBP1.1% of the fund-32%
- Indivior PharmaceuticalsINDV1.0% of the fund-5%
- Bicycle TherapeuticsBCYC0.7% of the fund-3%
- Monte Rosa TherapeuticsGLUE0.7% of the fund-58%
- MacrogenicsMGNX0.7% of the fund-38%
- Voyager TherapeuticsVYGR0.5% of the fund-2%
- EquilliumEQ0.5% of the fund-8%
- Harmony Biosciences HoldingsHRMY0.4% of the fund-71%
- Larimar TherapeuticsLRMR0.2% of the fund-12%
- Foghorn TherapeuticsFHTX0.1% of the fund-16%
- Aytu BiopharmaAYTU0.1% of the fund-58%
- UroGen PharmaURGN<0.1% of the fund-69%
- AnnexonANNX<0.1% of the fund-79%
- Upstream BioUPB<0.1% of the fund-12%
- MannkindMNKD<0.1% of the fund-91%
Sold out
Sold their entire stake.
- Bridgebio Pharma-100%
- Jazz PharmaceuticalsJAZZ-100%
- Terns Pharmaceuticals-100%
- IncyteINCY-100%
- TG TherapeuticsTGTX-100%
- BridgeBio PharmaBBIO-100%
- Eli LillyLLY-100%
- AbbVieABBV-100%
- Structure TherapeuticsGPCR-100%
- Tenax TherapeuticsTENX-100%
- Capricor TherapeuticsCAPR-100%
- EyePointEYPT-100%
- Climb BioCLYM-100%
- Shattuck LabsSTTK-100%
- Tarsus PharmaceuticalsTARS-100%
- Alkermes plc.ALKS-100%
- Vertex PharmaceuticalsVRTX-100%
- Inovio PharmaceuticalsINO-100%
- Dianthus TherapeuticsDNTH-100%
- Enanta PharmaceuticalsENTA-100%
- Replimune GroupREPL-100%
- Ultragenyx PharmaceuticalRARE-100%
- CelcuityCELC-100%
- uniQureQURE-100%
- Maze TherapeuticsMAZE-100%
Holdings
- Abivax SAABVX
- Share
- 8.2%
- Value
- $22m
- Shares
- 163,644
+115%
- Immunocore HldgsIMCR
- Share
- 3.1%
- Value
- $8m
- Shares
- 254,863
+32%
- Bicycle TherapeuticsBCYC
- Share
- 0.7%
- Value
- $2m
- Shares
- 462,724
-3%
- Helus PharmaHELP
- Share
- 0.5%
- Value
- $1m
- Shares
- 200,000
New
- JATT II AcquisitionJATT
- Share
- <0.1%
- Value
- $102,479
- Shares
- 9,021
New
- Kailera TherapeuticsKLRA
- Share
- <0.1%
- Value
- $79,771
- Shares
- 3,621
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| United TherapeuticsUTHR | 10.9% | $29m | 52,989 | +94% |
| Revolution MedicinesRVMD | 9.9% | $26m | 139,218 | +72% |
| Abivax SAABVX | 8.2% | $22m | 163,644 | +115% |
| Cogent BiosciencesCOGT | 7.2% | $19m | 493,664 | +53% |
| Biomarin PharmaceuticalBMRN | 6.8% | $18m | 312,846 | +111% |
| Viking TherapeuticsVKTX | 6.5% | $17m | 441,808 | -16% |
| Edgewise TherapeuticsEWTX | 4.2% | $11m | 272,214 | New |
| Kodiak SciencesKOD | 3.2% | $8m | 218,117 | +13% |
| Immunocore HldgsIMCR | 3.1% | $8m | 254,863 | +32% |
| 4D Molecular TherapeuticsFDMT | 2.9% | $8m | 571,107 | New |
| Arcus BiosciencesRCUS | 2.6% | $7m | 223,810 | -6% |
| Johnson & JohnsonJNJ | 2.1% | $6m | 22,000 | -59% |
| Novo Nordisk A SNVO | 1.8% | $5m | 100,000 | +586% |
| Corvus PharmaceuticalsCRVS | 1.7% | $4m | 294,811 | +20% |
| Relay TherapeuticsRLAY | 1.6% | $4m | 230,677 | New |
| ZymeworksZYME | 1.4% | $4m | 142,132 | Held |
| BioAge LabsBIOA | 1.4% | $4m | 146,334 | +144% |
| Taysha Gene TherapiesTSHA | 1.3% | $4m | 522,619 | New |
| Nurix TherapeuticsNRIX | 1.1% | $3m | 121,539 | New |
| Corbus Pharmaceuticals HoldingsCRBP | 1.1% | $3m | 301,264 | -32% |
| Indivior PharmaceuticalsINDV | 1.0% | $3m | 67,512 | -5% |
| InventivaIVA | 1.0% | $3m | 740,786 | +110% |
| Oruka TherapeuticsORKA | 1.0% | $3m | 27,799 | New |
| VaxcytePCVX | 1.0% | $3m | 45,071 | +80% |
| Relmada TherapeuticsRLMD | 0.9% | $3m | 361,367 | +80% |
| Vera TherapeuticsVERA | 0.9% | $2m | 57,608 | New |
| Contineum TherapeuticsCTNM | 0.7% | $2m | 119,733 | New |
| Bicycle TherapeuticsBCYC | 0.7% | $2m | 462,724 | -3% |
| Monte Rosa TherapeuticsGLUE | 0.7% | $2m | 78,391 | -58% |
| Viridian TherapeuticsVRDN | 0.7% | $2m | 100,000 | New |
| MacrogenicsMGNX | 0.7% | $2m | 374,403 | -38% |
| ProQR TherapeuticsPRQR | 0.7% | $2m | 926,016 | +414% |
| Spruce BiosciencesSPRB | 0.6% | $2m | 30,000 | +200% |
| ArdelyxARDX | 0.6% | $2m | 303,025 | New |
| Cue BiopharmaCUE | 0.6% | $2m | 48,369 | New |
| Mineralys TherapeuticsMLYS | 0.6% | $2m | 56,347 | +114% |
| Prothena Corp PublicPRTA | 0.6% | $1m | 149,482 | New |
| Voyager TherapeuticsVYGR | 0.5% | $1m | 413,642 | -2% |
| Unicycive TherapeuticsUNCY | 0.5% | $1m | 303,676 | +186% |
| Phathom PharmaceuticalsPHAT | 0.5% | $1m | 129,950 | +138% |
| Spyre TherapeuticsSYRE | 0.5% | $1m | 15,000 | New |
| Helus PharmaHELP | 0.5% | $1m | 200,000 | New |
| EquilliumEQ | 0.5% | $1m | 400,282 | -8% |
| Xeris Biopharma HoldingsXERS | 0.4% | $1m | 132,746 | Held |
| PharvarisPHVS | 0.4% | $1m | 29,321 | Held |
| Harmony Biosciences HoldingsHRMY | 0.4% | $978,118 | 26,864 | -71% |
| Cartesian TherapeuticsRNAC | 0.3% | $907,134 | 87,057 | New |
| Rigel PharmaceuticalsRIGL | 0.3% | $892,562 | 22,816 | New |
| Summit TherapeuticsSMMT | 0.3% | $874,200 | 60,000 | New |
| PrecigenPGEN | 0.3% | $771,170 | 135,293 | +145% |
| Definium TherapeuticsDFTX | 0.3% | $726,815 | 15,451 | New |
| Pelthos TherapeuticsPTHS | 0.3% | $700,085 | 24,773 | Held |
| PepGenPEPG | 0.3% | $671,911 | 373,284 | +147% |
| Enliven TherapeuticsELVN | 0.2% | $507,500 | 10,000 | +3982% |
| Connect Biopharma HoldingsCNTB | 0.2% | $468,824 | 196,985 | Held |
| Larimar TherapeuticsLRMR | 0.2% | $447,243 | 146,637 | -12% |
| Cellectar BiosciencesCLRB | 0.1% | $384,588 | 138,341 | New |
| Foghorn TherapeuticsFHTX | 0.1% | $326,511 | 66,908 | -16% |
| Aytu BiopharmaAYTU | 0.1% | $319,374 | 148,546 | -58% |
| OcugenOCGN | 0.1% | $306,000 | 200,000 | Held |
| UroGen PharmaURGN | <0.1% | $262,642 | 7,137 | -69% |
| AmgenAMGN | <0.1% | $214,645 | 102,701 | New |
| Heron TherapeuticsHRTX | <0.1% | $195,783 | 458,723 | New |
| TalpheraTLPH | <0.1% | $158,170 | 153,563 | Held |
| AnnexonANNX | <0.1% | $157,116 | 27,516 | -79% |
| Monopar TherapeuticsMNPR | <0.1% | $150,922 | 1,630 | Held |
| Lakeland IndustriesLAKE | <0.1% | $150,815 | 14,108 | New |
| Upstream BioUPB | <0.1% | $132,124 | 19,093 | -12% |
| MeiraGTx HoldingsMGTX | <0.1% | $113,052 | 8,368 | New |
| JATT II AcquisitionJATT | <0.1% | $102,479 | 9,021 | New |
| Kailera TherapeuticsKLRA | <0.1% | $79,771 | 3,621 | New |
| MannkindMNKD | <0.1% | $68,173 | 16,003 | -91% |
| Entera BioENTX | <0.1% | $41,170 | 23,260 | Held |
| ARS PharmaceuticalsSPRY | <0.1% | $38,929 | 4,860 | New |
| Aprea TherapeuticsAPRE | <0.1% | $36,029 | 44,907 | New |
| Tvardi TherapeuticsTVRD | <0.1% | $31,553 | 16,607 | New |
| NextCureNXTC | <0.1% | $12,387 | 7,742 | New |
Options (50)
- Viking TherapeuticsVKTX
- Type
- Call
- Value
- $48m
- Contracts
- 1,220,800
- Abivax SAABVX
- Type
- Call
- Value
- $47m
- Contracts
- 349,200
- Bristol-Myers SquibbBMY
- Type
- Call
- Value
- $35m
- Contracts
- 600,000
- Abivax SAABVX
- Type
- Put
- Value
- $34m
- Contracts
- 252,400
- Bristol-Myers SquibbBMY
- Type
- Put
- Value
- $19m
- Contracts
- 330,600
- Corcept TherapeuticsCORT
- Type
- Call
- Value
- $18m
- Contracts
- 206,300
- Kymera TherapeuticsKYMR
- Type
- Call
- Value
- $17m
- Contracts
- 149,700
- Novartis AGNVS
- Type
- Put
- Value
- $16m
- Contracts
- 100,000
- uniQureQURE
- Type
- Put
- Value
- $14m
- Contracts
- 299,000
- Viking TherapeuticsVKTX
- Type
- Put
- Value
- $14m
- Contracts
- 350,500
- BiogenBIIB
- Type
- Call
- Value
- $13m
- Contracts
- 60,000
- Capricor TherapeuticsCAPR
- Type
- Put
- Value
- $13m
- Contracts
- 534,400
- Summit TherapeuticsSMMT
- Type
- Call
- Value
- $13m
- Contracts
- 860,200
- Eli LillyLLY
- Type
- Put
- Value
- $12m
- Contracts
- 10,000
- IncyteINCY
- Type
- Put
- Value
- $12m
- Contracts
- 105,400
- uniQureQURE
- Type
- Call
- Value
- $11m
- Contracts
- 235,400
- Biontech SEBNTX
- Type
- Call
- Value
- $9m
- Contracts
- 100,000
- Capricor TherapeuticsCAPR
- Type
- Call
- Value
- $8m
- Contracts
- 329,300
- Novartis AGNVS
- Type
- Call
- Value
- $8m
- Contracts
- 50,000
- Replimune GroupREPL
- Type
- Call
- Value
- $8m
- Contracts
- 696,300
- Kodiak SciencesKOD
- Type
- Call
- Value
- $8m
- Contracts
- 196,700
- ModernaMRNA
- Type
- Put
- Value
- $7m
- Contracts
- 100,000
- Hims & Hers HealthHIMS
- Type
- Call
- Value
- $7m
- Contracts
- 200,000
- Hims & Hers HealthHIMS
- Type
- Put
- Value
- $7m
- Contracts
- 193,700
- Corbus Pharmaceuticals HoldingsCRBP
- Type
- Call
- Value
- $6m
- Contracts
- 633,800
- SELLAS Life Sciences GroupSLS
- Type
- Call
- Value
- $6m
- Contracts
- 400,000
- Kodiak SciencesKOD
- Type
- Put
- Value
- $6m
- Contracts
- 146,900
- AlumisALMS
- Type
- Call
- Value
- $6m
- Contracts
- 200,000
- Royalty PharmaRPRX
- Type
- Call
- Value
- $6m
- Contracts
- 100,000
- Replimune GroupREPL
- Type
- Put
- Value
- $6m
- Contracts
- 502,500
- BioAge LabsBIOA
- Type
- Call
- Value
- $5m
- Contracts
- 200,100
- BiohavenBHVN
- Type
- Call
- Value
- $5m
- Contracts
- 317,000
- Tenax TherapeuticsTENX
- Type
- Call
- Value
- $4m
- Contracts
- 307,000
- TG TherapeuticsTGTX
- Type
- Call
- Value
- $4m
- Contracts
- 75,700
- Monte Rosa TherapeuticsGLUE
- Type
- Call
- Value
- $4m
- Contracts
- 170,100
- Arcus BiosciencesRCUS
- Type
- Call
- Value
- $4m
- Contracts
- 124,000
- Unicycive TherapeuticsUNCY
- Type
- Call
- Value
- $4m
- Contracts
- 792,600
- AmgenAMGN
- Type
- Call
- Value
- $4m
- Contracts
- 10,000
- Intellia TherapeuticsNTLA
- Type
- Call
- Value
- $3m
- Contracts
- 200,000
- Celldex TherapeuticsCLDX
- Type
- Put
- Value
- $3m
- Contracts
- 86,000
- VaxcytePCVX
- Type
- Call
- Value
- $3m
- Contracts
- 53,100
- Summit TherapeuticsSMMT
- Type
- Put
- Value
- $3m
- Contracts
- 200,000
- VaxcytePCVX
- Type
- Put
- Value
- $3m
- Contracts
- 48,900
- Novo Nordisk A SNVO
- Type
- Put
- Value
- $3m
- Contracts
- 55,900
- CytokineticsCYTK
- Type
- Put
- Value
- $3m
- Contracts
- 30,000
- Vera TherapeuticsVERA
- Type
- Put
- Value
- $2m
- Contracts
- 50,000
- CelcuityCELC
- Type
- Call
- Value
- $2m
- Contracts
- 20,000
- AnnexonANNX
- Type
- Call
- Value
- $2m
- Contracts
- 353,200
- SepternaSEPN
- Type
- Put
- Value
- $2m
- Contracts
- 59,700
- Corvus PharmaceuticalsCRVS
- Type
- Call
- Value
- $2m
- Contracts
- 133,400
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 64.5% since 30 June 2025.
Where the money is
Health care88.0%
Financial services0.0%
Other12.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.